However, the opposite prognostic trends are reported for NDUFS3 and NDUFS5. In serous ovarian adenocarcinoma, the downregulation of NDUFS3 is related to advanced tumor stage and shorter overall survival (Wang et al., 2013); but in invasive breast carcinoma whose upregulation is positively aggressiveness-correlated biomarker signature (Suhane et al., 2011). Here, NDUFS5 is linked to neoplasm.